NCT03972917

Brief Summary

A prospective observational study on italian women undergoing ulipristal acetate (uPa) therapy for symptomatic myomas and its impact on symptomatology and moreover on myomas architecture. We also evaluate changes in the endometrial pattern of selected women.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
89

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2018

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2018

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

May 21, 2019

Completed
14 days until next milestone

First Posted

Study publicly available on registry

June 4, 2019

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 10, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 21, 2021

Completed
Last Updated

January 18, 2023

Status Verified

January 1, 2023

Enrollment Period

2.7 years

First QC Date

May 21, 2019

Last Update Submit

January 14, 2023

Conditions

Keywords

ulipristal acetatemyomaleiomyomaendometrial patternssymptomatology

Outcome Measures

Primary Outcomes (3)

  • Dysmenhorrea (VAS score)

    12 months

  • Endometrial thickess (mm)

    12 months

  • Myoma's diameter (mm)

    12 months

Secondary Outcomes (1)

  • Live birth rate (LBR)

    12 months

Study Arms (1)

ulipristal acetate based therapy

Fertile women under ulipristal acetate treatment

Diagnostic Test: Transvaginal ultrasonographic examination

Interventions

Evaluation of endometrial thickness; myoma size and volume

ulipristal acetate based therapy

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Italian fertile women who are eligible for conservative treatment for uterine fibroids

You may qualify if:

  • number of myomas from 1 to 4
  • heavy menstrual bleeding
  • conservative treatment request

You may not qualify if:

  • concurrent endometrial pathology
  • post-menopausal status
  • hepatic pathology
  • endocrine or metabolic disorders

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli"

Naples, Italy

Location

MeSH Terms

Conditions

MyomaMetrorrhagiaDysmenorrheaEndometrial HyperplasiaLeiomyoma

Condition Hierarchy (Ancestors)

Neoplasms, Muscle TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsUterine HemorrhageUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesHemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsMenstruation DisturbancesPelvic PainPainNeurologic ManifestationsSigns and Symptoms

Study Officials

  • Gaetano Riemma, MD

    University of Campania Luigi Vanvitelli

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

May 21, 2019

First Posted

June 4, 2019

Study Start

November 1, 2018

Primary Completion

July 10, 2021

Study Completion

September 21, 2021

Last Updated

January 18, 2023

Record last verified: 2023-01

Locations